Sellas Life Sciences Group Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Sellas Announces Positive Topline Data From GFH009 Phase 1 Dose-Escalation Trial
Brief: Sellas Life Sciences Successfully Completes Phase I Trial Dose Escalation Of Novel, Highly Selective Cdk9 Inhibitor Gfh009 In Acute Myeloid Leukemia
Brief: Sellas Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S Regal Trial To Continue As Planned
Brief: Sellas Life Sciences Reports Full Year 2022 Financial Results And Provides Business Update
Brief: Sellas Life Sciences Group Announces Publication Of Positive GPS Clinical Data In Ovarian Cancer In Peer Reviewed Journal
U.S. STOCKS ON THE MOVE-Intuit, Protalix, Unity Software
U.S. STOCKS ON THE MOVE- Adobe, Beyond Meat, Boeing
U.S. STOCKS ON THE MOVE-HF Sinclair Corp, Akebia Therapeutics, Gold miners
Brief: Sellas Life Sciences Announces Pricing Of $20 Mln Underwritten Public Offering
Sellas Life Sciences plunges on $20 mln stock-and-warrants offering
Brief: Sellas Life Sciences Announces Proposed Underwritten Public Offering
Sellas Life Sciences plunges on stock-and-warrants deal
Brief: Sellas Life Sciences Group Inc Says Appointed John Burns As CFO
Brief: SELLAS Announces Positive Phase 1 Data With CDK9 Inhibitor GFH009 Monotherapy In Patients With Relapsed Hematologic Malignancies
Brief: Sellas Life Sciences' Committee Recommends Galinpepimut-S Regal Trial To Continue As Planned
Brief: Sellas Life Sciences’ Cdk9 Inhibitor Gfh009 Demonstrates Tumor Growth Inhibition In Small Cell Lung Cancer Murine Model
Brief: Sellas Life Sciences Provides Business Update And Reports Q3 Financial Results
Brief: Sellas Life Sciences Announces Update On Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, In Acute Myeloid Leukemia